| Ytd | -29.92% | |
| 1y | -44.32% |
| Open | 4.18 | Prev Close | 4.20 | Low | 4.15 | High | 4.40 | Mkt Cap | 412.25M |
| Vol | 1.37M | Avg Vol | 2.04M | EPS | -1.18 | P/E | N/A | Forward P/E | 71.53 |
| Beta | 1.89 | Short Ratio | 4.83 | Inst. Own | 103.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-02 | 50-d Avg | 3.58 | 200-d Avg | 4.70 | 1yr Est | 19.41 |
MYGN News
SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaborati
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASD
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN),
Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises th
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday&#
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to
RH shares jumped 8.2% premarket after EPS beat estimates despite a revenue miss; Oracle and others g
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price tar
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesda
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Wei
Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the
Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, material
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analys
Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr
Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's
Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to
Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analys
Myriad Genetics Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price tar
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight
Myriad Genetics (NASDAQ:MYGN) sees FY2026 sales of $860.000 million-$880.000 million vs $867.455 mil
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.04 per share which beat the analyst
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine
Piper Sandler analyst Dave Weiner maintains Myriad Genetics (NASDAQ:MYGN) with a Overweight and l
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medici
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medici
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight
TD Cowen analyst Dan Brennan maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the p
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and raises the price tar
Myriad Genetics (NASDAQ:MYGN) affirms FY2025 Adj EPS guidance from $(0.02)-$0.02 to $(0.02)-$0.02 vs
Myriad Genetics (NASDAQ:MYGN) reported quarterly sales of $205.700 million which beat the analyst co